Adia Med Submits Second Clinical Study for Lower Back Pain, Launches Redesigned Website

Adia Med Inc. (OTCQB: ADIA), formerly Adia Nutrition Inc., has submitted its second clinical study for Institutional Review Board (IRB) review, evaluating the efficacy of AdiaVita, its proprietary umbilical cord blood-derived stem cell and exosome product, in alleviating lower back pain through non-invasive intravenous (IV) administration.

The single-blind, placebo-controlled trial will randomize approximately 100 participants into two groups: one receiving AdiaVita via IV and the other receiving a placebo. The primary objective is to assess AdiaVita's ability to reduce inflammation and promote repair of damaged tissue in the lower back. The study features a crossover design, in which after an initial three-month treatment period, participants in the placebo group will receive AdiaVita for the subsequent phase, enabling within-subject comparisons and extended evaluation of effects. Unlike conventional treatments that often involve ultrasound-guided injections directly into the affected area, this protocol tests systemic delivery via simple IV infusion. Participation is structured as a patient-pay model at $5,000 per patient, with no additional cost for the crossover phase. Enrollment is anticipated to commence upon IRB approval and acceptance on clinicaltrials.gov.

This submission follows Adia Med's ongoing flagship clinical research in Autism Spectrum Disorder (ASD). The IRB-approved 24-month study (ClinicalTrials.gov NCT07304440), titled "Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study," continues to actively recruit children aged 3-12. The trial, which aims to enroll approximately 100 participants, investigates whether combining AdiaVita with glutathione therapy yields greater improvements in ASD symptoms compared to glutathione alone, with every participant receiving AdiaVita treatments three times during the interventional phase.

Separately, Adia Med Inc. announced the launch of its redesigned corporate website at www.adiamed.com. The launch follows the company's recent name change from Adia Nutrition Inc. to Adia Med Inc., a strategic move to better align its brand with its core focus on regenerative medicine, stem cell therapies, and advanced biologics. The new website features sections on clinical studies, stem cell therapies, aesthetics, media coverage, podcasts, clinical case studies, investor information, regulatory filings, and company news. The former website, www.adianutrition.com, now automatically redirects visitors to the new site. "This redesigned website marks another important step forward for Adia Med Inc.," said the company's CEO. "Following our name change, we wanted a digital presence that better reflects who we are today."

Adia Med Inc., based in Winter Park, Florida, is a publicly traded clinical-stage regenerative medicine company. It specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division Adia Labs LLC, which is expanding to include insurance-billable wound care products. The company is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair, and offering regenerative treatments including stem cell therapies, platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT). Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. The company also invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company.